Literature DB >> 25464917

Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Ikwunga Wonodi1, Robert P McMahon2, Nithin Krishna2, Braxton D Mitchell3, Judy Liu2, Matthew Glassman2, L Elliot Hong2, James M Gold2.   

Abstract

BACKGROUND: Cognitive deficits compromise quality of life and productivity for individuals with schizophrenia and have no effective treatments. Preclinical data point to the kynurenine pathway of tryptophan metabolism as a potential target for pro-cognitive drug development. We have previously demonstrated association of a kynurenine 3-monooxygenase (KMO) gene variant with reduced KMO gene expression in postmortem schizophrenia cortex, and neurocognitive endophenotypic deficits in a clinical sample. KMO encodes kynurenine 3-monooxygenase (KMO), the rate-limiting microglial enzyme of cortical kynurenine metabolism. Aberration of the KMO gene might be the proximal cause of impaired cortical kynurenine metabolism observed in schizophrenia. However, the relationship between KMO variation and cognitive function in schizophrenia is unknown. This study examined the effects of the KMO rs2275163C>T C (risk) allele on cognitive function in schizophrenia.
METHODS: We examined the association of KMO polymorphisms with general neuropsychological performance and P50 gating in a sample of 150 schizophrenia and 95 healthy controls.
RESULTS: Consistent with our original report, the KMO rs2275163C>T C (risk) allele was associated with deficits in general neuropsychological performance, and this effect was more marked in schizophrenia compared with controls. Additionally, the C (Arg452) allele of the missense rs1053230C>T variant (KMO Arg452Cys) showed a trend effect on cognitive function. Neither variant affected P50 gating.
CONCLUSIONS: These data suggest that KMO variation influences a range of cognitive domains known to predict functional outcome. Extensive molecular characterization of this gene would elucidate its role in cognitive function with implications for vertical integration with basic discovery.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Genetic association; KMO; Kynurenine; P50; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25464917      PMCID: PMC4516229          DOI: 10.1016/j.schres.2014.10.026

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  121 in total

1.  Cognition in schizophrenia: from basic science to clinical treatment.

Authors:  Philip D Harvey; Mark A Geyer; Trevor W Robbins; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

2.  Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Edson X Albuquerque
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

3.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

4.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

5.  Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population.

Authors:  N Aoyama; N Takahashi; S Saito; N Maeno; R Ishihara; X Ji; H Miura; M Ikeda; T Suzuki; T Kitajima; Y Yamanouchi; Y Kinoshita; K Yoshida; N Iwata; T Inada; N Ozaki
Journal:  Genes Brain Behav       Date:  2006-06       Impact factor: 3.449

6.  Learning and forgetting in schizophrenia.

Authors:  J M Gold; G Rehkemper; S W Binks; C J Carpenter; K Fleming; T E Goldberg; D R Weinberger
Journal:  J Abnorm Psychol       Date:  2000-08

7.  Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia.

Authors:  Ashley K Smith; J Christopher Edgar; Mingxiong Huang; Brett Y Lu; Robert J Thoma; Faith M Hanlon; Greg McHaffie; Aaron P Jones; Rodrigo D Paz; Gregory A Miller; José M Cañive
Journal:  Am J Psychiatry       Date:  2010-07-15       Impact factor: 18.112

8.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

Review 9.  An expanding range of targets for kynurenine metabolites of tryptophan.

Authors:  Trevor W Stone; Nicholas Stoy; L Gail Darlington
Journal:  Trends Pharmacol Sci       Date:  2012-11-01       Impact factor: 14.819

10.  Genome-wide association analysis identifies 13 new risk loci for schizophrenia.

Authors:  Stephan Ripke; Colm O'Dushlaine; Kimberly Chambert; Jennifer L Moran; Anna K Kähler; Susanne Akterin; Sarah E Bergen; Ann L Collins; James J Crowley; Menachem Fromer; Yunjung Kim; Sang Hong Lee; Patrik K E Magnusson; Nick Sanchez; Eli A Stahl; Stephanie Williams; Naomi R Wray; Kai Xia; Francesco Bettella; Anders D Borglum; Brendan K Bulik-Sullivan; Paul Cormican; Nick Craddock; Christiaan de Leeuw; Naser Durmishi; Michael Gill; Vera Golimbet; Marian L Hamshere; Peter Holmans; David M Hougaard; Kenneth S Kendler; Kuang Lin; Derek W Morris; Ole Mors; Preben B Mortensen; Benjamin M Neale; Francis A O'Neill; Michael J Owen; Milica Pejovic Milovancevic; Danielle Posthuma; John Powell; Alexander L Richards; Brien P Riley; Douglas Ruderfer; Dan Rujescu; Engilbert Sigurdsson; Teimuraz Silagadze; August B Smit; Hreinn Stefansson; Stacy Steinberg; Jaana Suvisaari; Sarah Tosato; Matthijs Verhage; James T Walters; Douglas F Levinson; Pablo V Gejman; Kenneth S Kendler; Claudine Laurent; Bryan J Mowry; Michael C O'Donovan; Michael J Owen; Ann E Pulver; Brien P Riley; Sibylle G Schwab; Dieter B Wildenauer; Frank Dudbridge; Peter Holmans; Jianxin Shi; Margot Albus; Madeline Alexander; Dominique Campion; David Cohen; Dimitris Dikeos; Jubao Duan; Peter Eichhammer; Stephanie Godard; Mark Hansen; F Bernard Lerer; Kung-Yee Liang; Wolfgang Maier; Jacques Mallet; Deborah A Nertney; Gerald Nestadt; Nadine Norton; Francis A O'Neill; George N Papadimitriou; Robert Ribble; Alan R Sanders; Jeremy M Silverman; Dermot Walsh; Nigel M Williams; Brandon Wormley; Maria J Arranz; Steven Bakker; Stephan Bender; Elvira Bramon; David Collier; Benedicto Crespo-Facorro; Jeremy Hall; Conrad Iyegbe; Assen Jablensky; Rene S Kahn; Luba Kalaydjieva; Stephen Lawrie; Cathryn M Lewis; Kuang Lin; Don H Linszen; Ignacio Mata; Andrew McIntosh; Robin M Murray; Roel A Ophoff; John Powell; Dan Rujescu; Jim Van Os; Muriel Walshe; Matthias Weisbrod; Durk Wiersma; Peter Donnelly; Ines Barroso; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden P Corvin; Panos Deloukas; Audrey Duncanson; Janusz Jankowski; Hugh S Markus; Christopher G Mathew; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Richard C Trembath; Ananth C Viswanathan; Nicholas W Wood; Chris C A Spencer; Gavin Band; Céline Bellenguez; Colin Freeman; Garrett Hellenthal; Eleni Giannoulatou; Matti Pirinen; Richard D Pearson; Amy Strange; Zhan Su; Damjan Vukcevic; Peter Donnelly; Cordelia Langford; Sarah E Hunt; Sarah Edkins; Rhian Gwilliam; Hannah Blackburn; Suzannah J Bumpstead; Serge Dronov; Matthew Gillman; Emma Gray; Naomi Hammond; Alagurevathi Jayakumar; Owen T McCann; Jennifer Liddle; Simon C Potter; Radhi Ravindrarajah; Michelle Ricketts; Avazeh Tashakkori-Ghanbaria; Matthew J Waller; Paul Weston; Sara Widaa; Pamela Whittaker; Ines Barroso; Panos Deloukas; Christopher G Mathew; Jenefer M Blackwell; Matthew A Brown; Aiden P Corvin; Mark I McCarthy; Chris C A Spencer; Elvira Bramon; Aiden P Corvin; Michael C O'Donovan; Kari Stefansson; Edward Scolnick; Shaun Purcell; Steven A McCarroll; Pamela Sklar; Christina M Hultman; Patrick F Sullivan
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

View more
  17 in total

Review 1.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 2.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

3.  The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia.

Authors:  Martina Ulivieri; Joanna Monika Wierońska; Luana Lionetto; Katiuscia Martinello; Paulina Cieslik; Agnieszka Chocyk; Martina Curto; Luisa Di Menna; Luisa Iacovelli; Anna Traficante; Francesca Liberatore; Giada Mascio; Nico Antenucci; Giuseppe Giannino; Matteo Vergassola; Anna Pittaluga; Valeria Bruno; Giuseppe Battaglia; Sergio Fucile; Maurizio Simmaco; Ferdinando Nicoletti; Andrzej Pilc; Francesco Fazio
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 4.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

Review 5.  Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.

Authors:  R Schwarcz
Journal:  Adv Pharmacol       Date:  2016-03-11

6.  Sex-specific variation in signaling pathways and gene expression patterns in human leukocytes in response to endotoxin and exercise.

Authors:  Asghar Abbasi; Rodolfo de Paula Vieira; Felix Bischof; Michael Walter; Masoud Movassaghi; Nicole C Berchtold; Andreas M Niess; Carl W Cotman; Hinnak Northoff
Journal:  J Neuroinflammation       Date:  2016-11-10       Impact factor: 8.322

Review 7.  Major Developments in the Design of Inhibitors along the Kynurenine Pathway.

Authors:  Kelly R Jacobs; Gloria Castellano-Gonzalez; Gilles J Guillemin; David B Lovejoy
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

Review 8.  The kynurenine pathway: a finger in every pie.

Authors:  Jonathan Savitz
Journal:  Mol Psychiatry       Date:  2019-04-12       Impact factor: 15.992

9.  Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.

Authors:  C M Forrest; K McNair; M Pisar; O S Khalil; L G Darlington; T W Stone
Journal:  Neuroscience       Date:  2015-09-10       Impact factor: 3.590

10.  Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.

Authors:  Maju Mathew Koola
Journal:  Schizophr Res Cogn       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.